GDF-15 Antibody (ponsegromab) [PE]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28880PE
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
ELISA, Flow Cytometry, Functional
Label
PE (Excitation = 488 nm, Emission = 575 nm)
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # ponsegromab
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for GDF-15 Antibody (ponsegromab) [PE]
Immunogen
GDF15 / MIC1
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Applications for GDF-15 Antibody (ponsegromab) [PE]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: GDF-15
GDF15 antibodies are useful for studies on inflamation and immune system research.
Long Name
Growth Differentiation Factor 15
Alternate Names
GDF15, MIC-1, NAG-1, PDF, PLAB, PTGF-beta
Gene Symbol
GDF15
Additional GDF-15 Products
Product Documents for GDF-15 Antibody (ponsegromab) [PE]
Product Specific Notices for GDF-15 Antibody (ponsegromab) [PE]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...